Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about GILEAD SCIENCES, INC.
01/24U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments
RE
01/24Gilead Sciences-FDA Approves Veklury (Remdesivir) for the Treatment of Non-Hospitalized..
AQ
01/24Gilead Secures FDA Approval for Veklury in Non-Hospitalized COVID-19 Patients at High R..
MT
01/21Gilead Gets FDA Approval for Remdesivir for Some Non-Hospitalized Patients
DJ
01/21FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at Hi..
BU
01/21Gilead Sciences, Inc. Announces FDA Approves Veklury® for the Treatment of Non-Hospital..
CI
01/19GLOBAL MARKETS LIVE : Bank of America, ASML, Intel, Oracle, Burberry...
01/19WALL STREET STOCK EXCHANGE : Temporary respite for the Nasdaq
01/19MARKETSCREENER’S WORLD PRESS REVIEW : January 19, 2022
01/19ANALYST RECOMMENDATIONS : Activision Blizzard, Chevron, Exxon Mobil, Gilead, Goldman Sachs..
01/19GILEAD SCIENCES : Announces Actions to Remove Counterfeit HIV Medications from U.S. Supply..
PU
01/18Gilead says counterfeit HIV drugs ended up with patients
RE
01/18Health Care Down Amid Flight From Cyclical Sectors -- Health Care Roundup
DJ
01/18Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday..
BU
01/18Morgan Stanley Lowers Price Target for Gilead Sciences to $72 From $74, Maintains Equal..
MT
01/18Gilead says counterfeiting network sold $250 mln worth of its HIV drugs
RE
01/14Gilead withdraws use of Zydelig to treat two types of cancer
RE
01/14Gilead withdraws use of Zydelig to treat two types of cancer
RE
01/14GILEAD SCIENCES : Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small ..
PU
01/13UK's Countryside Properties plunges as CEO leaves after weak quarter
RE
01/13Countryside Slumps 17% as CEO Steps Down Amid Deal with Activist Investor
MT
01/13Countryside Properties CEO Steps Down; Chair Named As Interim Successor
MT
01/12TONY XU : All Eyes on -2-
DJ
01/11GLOBAL MARKETS LIVE : Airbus, Nokia, Pandora, Darktrace, Amazon...
01/11Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy in Combi..
AQ
01/10Gilead, Merck & Co. to Evaluate Lung Cancer Combo Therapy in Two Clinical Studies
MT
01/10Gilead Sciences, Merck To Study Trodelvy, Keytruda Combination For Treatment of Lung Ca..
MT
01/10Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Comb..
BU
01/10Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Comb..
CI
01/07NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
01/06Gilead Sciences, Inc. Announces Retirement of Brett A. Pletcher as Executive Vice Presi..
CI
01/06Today on Wall Street: A hard pill to swallow
01/06Morgan Stanley Downgrades Gilead Sciences to Equalweight From Overweight, Cuts Price Ta..
MT
01/06RBC Lifts Price Target on Gilead Sciences to $87 From $86, Maintains Outperform Rating
MT
01/06ANALYST RECOMMENDATIONS : Bank of America, Dollar General, Evercore, Reckitt Benckiser, Un..
2021COVID-19 Vaccine Names May Face 'Volatile' 2022, Oppenheimer Says
MT
2021-Russia extends production of COVID-19 drug remdesivir without patent for a year
RE
2021Russia extends production of COVID-19 drug remdesivir without patent for a year
RE
2021NRX Pharmaceuticals Seeks FDA's Breakthrough Therapy Status For COVID-19 Therapy Zyesam..
MT
2021Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Vekl..
AQ
2021NORTH AMERICAN MORNING BRIEFING : Stocks to Rise on Encouraging Virus Studies
DJ
2021Pardes Biosciences, Inc. announced that it has received $75 million in funding from a g..
CI
2021Gilead Sciences Says Its Remdesivir Drug Lowers Risk of Hospitalization in High-Risk CO..
MT
2021Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Vekl..
BU
2021Gilead Sciences, Inc. - European Commission Expands Indication for Veklury (Remdesivir)..
AQ
2021Gilead Sciences' Lenacapavir Trials Put on FDA Hold Over Vial Quality Issues
MT
2021Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Tre..
BU
2021Gilead Sciences, Inc. Announces Clinical Hold on Studies Evaluating Injectable Lenacapa..
CI
2021Gilead Sciences, Inc. and Arcus Biosciences, Inc. Complete Closing of Option Exercise f..
CI
2021Gilead Sciences to Present at Upcoming Investor Conference
BU
2021European Commission Expands Indication for Gilead's COVID-19 Treatment Remdesivir
MT
2021European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Ad..
BU
2021Gilead Sciences, Inc. Announces European Commission Approves Variation to the Condition..
CI
2021FDA approves injectable form of GSK HIV prevention drug
RE
2021TIMELINE-Key moments of COVID-19 pandemic
RE
2021Gilead Sciences Unit, Daiichi Sankyo Launch Cell Therapy Product in Japan
MT
2021EU drug regulator won't rule on Merck COVID-19 pill before Christmas - source
RE
2021Glympse Bio, Inc. announced that it has received $64.699965 million in funding
CI
2021Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Ther..
BU
2021Kite and Daiichi Sankyo Company, Limited Announces YESCARTA (Axicabtagene Ciloleucel), ..
CI
2021NRX Pharma Says COVID-19 Drug Candidate Zyesami Raises No New Safety Concerns in Late-S..
MT
2021GILEAD SCIENCES, INC. : Ex-dividend day for
FA
2021Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line T..
BU
2021Kite Announces Primary Results from ZUMA-12, Global, Multicenter, Single-Arm, Open-Labe..
CI
2021Kite - Yescarta CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration over ..
AQ
2021Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Ref..
BU
2021Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal St..
BU
2021Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standa..
BU
2021Gilead Company Announces Results from the Primary Analysis of Zuma-7
CI
2021GILEAD : Trodelvy Demonstrates Benefit for Black Patients Consistent with Full Metastatic ..
DJ
2021After centuries, Belgian nuns make beer
RE
2021Gilead Sciences' Trodelvy Study Shows Clinical Benefit for Black Patients
MT
2021Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metasta..
BU
2021Gilead Sciences, Inc. Announces Trodelvy® Demonstrates Clinical Benefit for Black Patie..
CI
2021China Development Bank Financial Leasing Unit to Dispose of Two Boeing Aircraft
MT
1  2  3  4  5  6  7  8  9  10Next
Official Publications
Upcoming event on GILEAD SCIENCES, INC.
02/01/22